Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
0.8952
Dollar change
-0.0723
Percentage change
-7.47
%
Index- P/E- EPS (ttm)-1.38 Insider Own16.27% Shs Outstand225.41M Perf Week-13.09%
Market Cap201.94M Forward P/E- EPS next Y-0.70 Insider Trans0.51% Shs Float188.87M Perf Month-37.40%
Income-179.82M PEG- EPS next Q-0.19 Inst Own79.44% Short Float5.70% Perf Quarter-3.46%
Sales0.00M P/S- EPS this Y35.82% Inst Trans11.74% Short Ratio8.45 Perf Half Y34.45%
Book/sh0.28 P/B3.21 EPS next Y6.95% ROA-61.54% Short Interest10.76M Perf Year-14.74%
Cash/sh1.31 P/C0.68 EPS next 5Y5.20% ROE-480.50% 52W Range0.45 - 1.88 Perf YTD-1.90%
Dividend Est.- P/FCF- EPS past 5Y11.99% ROI-69.08% 52W High-52.38% Beta1.76
Dividend TTM- Quick Ratio5.94 Sales past 5Y0.00% Gross Margin- 52W Low97.83% ATR (14)0.10
Dividend Ex-Date- Current Ratio5.94 EPS Y/Y TTM49.48% Oper. Margin0.00% RSI (14)30.29 Volatility9.09% 8.23%
Employees135 Debt/Eq3.38 Sales Y/Y TTM- Profit Margin- Recom1.80 Target Price5.72
Option/ShortYes / Yes LT Debt/Eq3.15 EPS Q/Q63.89% Payout- Rel Volume1.08 Prev Close0.97
Sales Surprise- EPS Surprise-0.82% Sales Q/Q- EarningsMar 05 BMO Avg Volume1.27M Price0.90
SMA20-26.07% SMA50-23.96% SMA200-10.93% Trades Volume1,376,945 Change-7.47%
Date Action Analyst Rating Change Price Target Change
Apr-05-24Resumed Wedbush Outperform $4
Jul-27-23Downgrade UBS Buy → Neutral $8 → $1.25
Mar-07-23Downgrade Raymond James Outperform → Mkt Perform
Mar-01-23Initiated Guggenheim Neutral
Dec-07-22Downgrade SMBC Nikko Outperform → Neutral $3
Dec-07-22Downgrade JP Morgan Neutral → Underweight
Dec-07-22Downgrade Barclays Overweight → Equal Weight $18 → $2
Oct-20-22Initiated Goldman Buy $22
Sep-21-22Initiated JP Morgan Neutral $17
Sep-19-22Initiated Wedbush Outperform $24
Mar-13-24 07:07AM
Mar-12-24 07:31AM
Mar-07-24 09:55AM
Mar-05-24 10:52PM
07:55AM
07:40AM Loading…
07:40AM
07:31AM
Feb-27-24 03:30AM
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM
Nov-29-23 07:01AM
08:11AM Loading…
Nov-09-23 08:11AM
07:41AM
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM Loading…
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
07:31AM
Mar-07-23 03:37PM
Mar-03-23 11:40AM
Feb-01-23 04:25PM
Jan-04-23 12:00PM
09:35AM
Dec-26-22 09:41AM
Dec-06-22 01:19PM
10:00AM
08:19AM
07:15AM
Nov-17-22 02:37PM
Nov-08-22 12:00PM
Nov-03-22 04:01PM
Oct-24-22 08:30AM
Aug-29-22 08:11AM
Aug-09-22 08:01AM
Jul-21-22 06:21PM
Jul-20-22 11:33AM
Jul-19-22 12:00PM
09:46AM
Jul-18-22 09:55AM
Jul-13-22 07:15AM
Jun-09-22 08:30AM
May-26-22 09:55AM
May-23-22 09:55AM
May-10-22 04:01PM
May-06-22 12:20PM
Apr-25-22 07:29AM
Mar-03-22 04:01PM
Feb-28-22 07:01AM
Jan-02-22 08:47AM
Nov-08-21 04:01PM
Nov-02-21 04:01PM
Oct-11-21 08:36AM
Oct-07-21 04:01PM
Oct-03-21 10:45AM
Sep-21-21 08:31AM
Aug-09-21 04:01PM
Aug-02-21 04:01PM
Jul-21-21 05:16AM
Jul-17-21 05:47AM
Jul-07-21 07:01AM
Jun-21-21 04:01PM
Jun-14-21 04:01PM
May-06-21 07:31AM
Apr-20-21 07:50AM
Apr-16-21 07:55AM
Feb-25-21 07:31AM
Feb-19-21 08:01AM
Feb-04-21 07:05AM
Jan-18-21 03:05AM
Dec-19-20 03:54PM
Dec-11-20 05:00PM
Dec-07-20 07:03AM
Nov-16-20 07:01AM
Nov-10-20 04:01PM
02:30PM
08:00AM
Nov-06-20 07:07AM
07:03AM
Oct-13-20 03:02PM
07:04AM
Oct-12-20 08:07AM
Oct-09-20 08:01AM
Sep-30-20 08:38AM
Sep-10-20 07:07AM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hasnain FaheemPresident & CEOMar 27 '24Sale1.1623,17226,773120,293Mar 28 06:01 PM
Giraudo BryanCOO/CFOMar 27 '24Sale1.166,4307,43192,737Mar 28 06:05 PM
Christian WaageEVP, Tech Ops and AdminMar 27 '24Sale1.166,4307,430585,934Mar 28 06:16 PM
Peterson CarynEVP, Regulatory AffairsMar 18 '24Sale1.334,0185,34349,833Mar 19 06:50 PM
Aranda RichardChief Medical OfficerMar 18 '24Sale1.334,0185,342198,799Mar 19 06:50 PM
Milligan SandraDirectorNov 15 '23Buy0.7932,00025,21332,000Nov 17 04:01 PM
Giraudo BryanCOO/CFONov 13 '23Buy0.56200,000112,880380,010Nov 14 06:24 PM
Aranda RichardChief Medical OfficerJun 22 '23Sale1.291,8142,340197,574Jun 26 04:01 PM